0.94
0.94 (0%)
As of Feb 14, 2025
Lava Therapeutics Nv [LVTX]
Source:
Company Overview
Lava Therapeutics Nv is a clinical stage immuno-oncology company focused on developing our proprietary Gammabody platform of bispecific gamma delta (gd) T cell engagers to transform the treatment of cancer.
| Country | Netherlands |
| Headquarters | utrecht, netherlands |
| Phone Number | 31 85 016 3100 |
| Industry | manufacturing |
| CEO | Stephen Hurly |
| Website | www.lavatherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $12 |
| Operating Profit | $-29.7 |
| Net Income | $-25.1 |
| Net Cash | $-7.6 |
Profit Ratios
| Gross Margin | $12 |
| Operating Margin | -247.8 |
| Profit as % of Revenues | -47.7% |
| Profit as % of Assets | -27.5% |
| Profit as % of Stockholder Equity | -90.5% |
Management Effectiveness
| Return on Equity | -90.5% |
| Return on Assets | -31.1% |
| Turnover Ratio | 13.1% |
| EBITA | $-29.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $80.8 |
| Total Liabilities | $53.1 |
| Operating Cash Flow | $-19.5 |
| Investing Cash Flow | $12.5 |
| Financing Cash Flow | $-0.6 |
